Le Lézard
Classified in: Science and technology, Business
Subjects: TNM, PER, SHA

Joffre Capital Unable to Proceed to Pre-Closing of Purchase Agreement to Acquire 106,102,467 shares of Playtika Stock Due to Issues with Seller and at the Company


Joffre Co-Founder and Managing Partner James Lu Resigns from Playtika Board of Directors

LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- Joffre Capital ("Joffre" or the "Firm") a global investment firm focused on control positions in leading consumer software, technology and internet businesses, today announced that, due to certain conditions at the Company and with Playtika Holding UK II Limited ("PHUKII"), it is unable at this time to proceed to pre-closing under the announced stock purchase agreement dated June 27 (the "Purchase Agreement") to acquire 106,102,467 shares of Playtika Holding Corp. (NASDA: PLTK) ("Playtika or the "Company") from PHUKII.

In addition, James Lu, Co-Founder and Managing Partner of Joffre, has resigned from the Playtika Board of Directors (the "Board"), effective November 30.  In a letter delivered to the Board on November 30, Mr. Lu outlines objections with the Company as reasons for his resignation, including:

"As long-term investors who believe deeply in Playtika's business, we are disappointed that we are unable to move forward with our acquisition of Company stock at this time," said Mr. Lu.  "We were excited about the opportunity to help Playtika capitalize on its market position and growth prospects.   Despite my immediate efforts to work with the Board to address the Company's deficient corporate governance practices, which were outlined in a letter I delivered to the Board on July 16, the Board has failed to act in a sufficiently meaningful manner.  After several months of attempting to work with PHUKII, it has become clear that Joffre is not able to proceed to pre-closing outlined in the Purchase Agreement in part due to Playtika management's domination of the Board, which is directly contrary to assurances made by PHUKII prior to signing the Purchase Agreement.  Pursuant to the terms in the Purchase Agreement, we will seek to recover our initial payment to PHUKII, which we have requested be returned immediately."

About Joffre Capital

Joffre Capital is a global investment firm focused on control positions in leading consumer software, technology and internet businesses.  Led by a team of entrepreneurs and technology executives with cross-regional experience and relationships, Joffre accelerates growth in its portfolio companies by bridging geography gaps and expanding into new products, services and markets.  The firm has multiple billion dollars under management and a presence across the US, Europe and Asia.  

Media Contacts
ASC Advisors
Steve Bruce / Taylor Ingraham
[email protected] / [email protected]
1-203-992-1230

SOURCE Joffre Capital


These press releases may also interest you

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: